

## BLOCK LISTING SIX MONTHLY RETURN

May 23, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Sharesave Scheme		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		163,520		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		4,132		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		159,388		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Portfolio Share Plan		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		270,534		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		101,940		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		168,594		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Employee Stock Purchase Plan		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		237,698		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		Nil		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		237,698		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Long Term Incentive Plan 2015		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		2,498,571		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		637,589		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		1,860,982		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Shire Global Employee Stock Purchase Plan		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		800,783		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		338		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		800,445		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Baxalta Exchange Awards		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		17,230,339		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		3,620,967		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		13,609,372		

Name of <i>applicant</i> :		Shire plc		
Name of scheme:		Combined block listing in respect of the Shire Portfolio Share Plan, the Shire Long Term Incentive Plan 2015 and the Shire Global Employee Stock Purchase Plan.		
Period of return:	From:	November 23, 2017	To:	May 22, 2018
Balance of unallotted securities under scheme(s) from previous return:		3,000,000		
<i>Plus</i> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<i>Less</i> : Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		Shire Portfolio Share Plan: Nil Shire Long Term Incentive Plan 2015: Nil Shire Global Employee Stock Purchase Plan: Nil		
<i>Equals</i> : Balance under scheme(s) not yet issued/allotted at end of period:		3,000,000		

Sarah Rixon  
Company Secretarial Assistant

**For further information please contact:**

**Investor Relations**

Christoph Brackmann	<a href="mailto:christoph.brackmann@shire.com">christoph.brackmann@shire.com</a>	+41 795 432 359
Sun Kim	<a href="mailto:sun.kim@shire.com">sun.kim@shire.com</a>	+1 617 588 8175
Robert Coates	<a href="mailto:rcoates@shire.com">rcoates@shire.com</a>	+44 203 549 0874

**Media**

Katie Joyce	<a href="mailto:kjoyce@shire.com">kjoyce@shire.com</a>	+1 781 482 2779
-------------	--------------------------------------------------------	-----------------

**NOTES TO EDITORS**

**About Shire**

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what's next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our Rare Disease and Neuroscience divisions support our diverse portfolio of therapeutic areas, including Immunology, Hematology, Genetic Diseases, Internal Medicine, Ophthalmics, Oncology, and neuropsychiatry disorders.

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people's lives.

[www.shire.com](http://www.shire.com)